Proteasome inhibitors in the treatment of nonsmall cell lung cancer: A systematic review of clinical evidence
Health Science Reports · 2023-11 · 6 (11)
DOI: 10.1002/hsr2.1443 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Health Science Reports, online erschienen am 13.11.2023. Verfasst von Alethea Dasha Wenning Chua und 3 weiteren Autor:innen. Beteiligte Einrichtung: Yong Loo Lin School of Medicine National University of Singapore Singapore Singapore. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and Aims Nonsmall cell lung cancer accounts for over 85% of lung cancer incidences worldwide, and often has a poor prognosis. Proteasome inhibitors, such as bortezomib, have previously demonstrated evidence in preclinical and clinical models in the treatment of NSCLC both alone and as part of chemotherapeutic regimens.
Methods
Five databases were searched from inception to February 2023 to identify published clinical trial data and ongoing clinical trials on the use of proteasome inhibitors in treatment of NSCLC with a comprehensive search strategy.
Results
This review examines the clinical evidence from 21 completed and published phase I and II trials studying the use of bortezomib monotherapy and combination therapy in the treatment of NSCLC. Bortezomib/docetaxel combination resulted in longer median time‐to‐progression (TTP), median duration of response, median duration of disease control and median progression‐free survival (PFS) than bortezomib monotherapy, with concurrent administration having greater 6‐month PFS and median overall survival (OS) than sequential administration. Bortezomib/vorinostat with chemotherapy was well tolerated and effective. Bortezomib/gemcitabine/carboplatin, bortezomib/bevacizumab/carboplatin and bortezomib/paclitaxel/carboplatin combinations showed promising results and were of further investigational value.
Conclusion
Bortezomib showed some clinical promise in combination therapy but not monotherapy. It also demonstrated a manageable side effect profile. Combination regimens are of further investigation value in Phase II trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Yong Loo Lin School of Medicine National University of Singapore Singapore Singapore.
ORCID-Profile: Alethea Dasha Wenning Chua, Ainsley Ryan Yan Bin Lee
Zitieren
APA
Chua, A. D. W., Thaarun, T., Yang, H., & Lee, A. R. Y. B. (2023). Proteasome inhibitors in the treatment of nonsmall cell lung cancer: A systematic review of clinical evidence. Health Science Reports, 6(11). https://doi.org/10.1002/hsr2.1443
Vancouver
Chua ADW, Thaarun T, Yang H, Lee ARYB. Proteasome inhibitors in the treatment of nonsmall cell lung cancer: A systematic review of clinical evidence. Health Science Reports. 2023;6(11). doi:10.1002/hsr2.1443
BibTeX
@article{Chua2023,
author = {Chua, Alethea Dasha Wenning and Thaarun, Thirumeninathan and Yang, Hui and Lee, Ainsley Ryan Yan Bin},
title = {Proteasome inhibitors in the treatment of nonsmall cell lung cancer: A systematic review of clinical evidence},
journal = {Health Science Reports},
year = {2023},
volume = {6},
number = {11},
doi = {10.1002/hsr2.1443}
}
EUVIMED